Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Advicenne    ADVIC   FR0013296746

ADVICENNE

(ADVIC)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
6.78(c) 6.78(c) 6.7(c) 7(c) 7 Last
2 949 1 195 2 982 11 174 8 Volume
0.00% 0.00% -1.18% +4.48% 0.00% Change
More quotes
Financials
Sales 2020 22,9 M 25,9 M 25,9 M
Net income 2020 -4,50 M -5,10 M -5,10 M
Net cash position 2020 10,7 M 12,1 M 12,1 M
P/E ratio 2020 -13,2x
Yield 2020 -
Sales 2021 12,3 M 13,9 M 13,9 M
Net income 2021 -12,0 M -13,6 M -13,6 M
Net Debt 2021 1,20 M 1,36 M 1,36 M
P/E ratio 2021 -4,90x
Yield 2021 -
Capitalization 58,9 M 66,6 M 66,7 M
EV / Sales 2020 2,10x
EV / Sales 2021 4,89x
Nbr of Employees 29
Free-Float 50,8%
More Financials
Company
Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children. At the end of 2018, the group had 2 products in clinical development phase, including ADV7103 in Phase III for the treatment of distal renal tubular acidosis and in Phase II/III for the treatment of cystinuria, and ADV6770 in Phase I for the treatment of... 
More about the company
Latest news on ADVICENNE
06/02ADVICENNE : May 26, 2020 - Advicenne Shareholders Adopt All Resolutions Recommen..
PU
05/25ADVICENNE : Gears Up for Accelerated Growth
BU
05/21ADVICENNE : May 5, 2020 - Advicenne Combined Shareholders Meeting to Be Held on ..
PU
05/05ADVICENNE : Combined Shareholders Meeting to Be Held on May 26 Behind Closed Doo..
BU
03/16ADVICENNE : Announces the Appointment of Andre Ulmann as Interim Chief Executive..
AQ
03/16ADVICENNE : Reports Full-Year 2019 Financial Results and Confirms Operational Ou..
AQ
03/13ADVICENNE : Reports Full-Year 2019 Financial Results and Confirms Operational Ou..
BU
03/13ADVICENNE : Announces the Appointment of André Ulmann as Interim Chief Executive..
BU
03/13ADVICENNE : Annual results
CO
03/13ADVICENNE : Nomination
CO
03/10ADVICENNE : Makes ADV7103 8 mEq and 24 mEq Prolonged-Release Granules Available ..
BU
01/28ADVICENNE : Publishes its Financial Calendar for 2020
BU
2019ADVICENNE : 's Lead Candidate Approved for Orphan Drug Designation in the Treatm..
BU
2019ADVICENNE : Publishes its 2019 Half-Year Financial Report
AQ
2019ADVICENNE : Advicenna Presents 2019 Half Year Financial Report and Confirms Fina..
AQ
More news
News in other languages on ADVICENNE
07/09ADVICENNE : Bilan semestriel du contrat de liquidité contracté avec la Société d..
06/02ADVICENNE : May 26, 2020 - Advicenne Shareholders Adopt All Resolutions Recommen..
05/26ADVICENNE : 26 mai 2020 - Advicenne annonce l'approbation de l'ensemble des réso..
05/26ADVICENNE : annonce l'approbation de l'ensemble des résolutions soutenues par le..
05/26EN DIRECT DES MARCHES : Sanofi, Renault, Scor, Vinci, Korian, Lufthansa, Siem..
More news
Chart ADVICENNE
Duration : Period :
Advicenne Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADVICENNE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 21,50 €
Last Close Price 7,00 €
Spread / Highest target 207%
Spread / Average Target 207%
Spread / Lowest Target 207%
EPS Revisions
Managers
NameTitle
André Ulmann Chief Executive Officer & Director
David Horn Solomon Non-Executive Chairman
Caroline Roussel-Maupetit Operations Director & General Manager
Sarah Delbaere Director-Financial & Logistics
Paul Michalet Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ADVICENNE-20.45%67
CSL LIMITED2.40%89 140
BIOGEN INC.-6.02%45 510
SAMSUNG BIOLOGICS CO.,LTD.68.82%40 291
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.125.11%25 551
WUXI BIOLOGICS (CAYMAN) INC.47.39%25 413